Brokers Issue Forecasts for CureVac’s Q1 2024 Earnings (NASDAQ:CVAC)

CureVac (NASDAQ:CVAC) – Stock analysts at Leerink Partnrs issued their Q1 2024 earnings per share estimates for CureVac in a research report issued to clients and investors on Friday, April 26th. Leerink Partnrs analyst M. Foroohar anticipates that the company will earn ($0.14) per share for the quarter. Leerink Partnrs has a “Market Perform” rating on the stock. The consensus estimate for CureVac’s current full-year earnings is ($0.97) per share. Leerink Partnrs also issued estimates for CureVac’s Q2 2024 earnings at ($0.14) EPS, Q3 2024 earnings at ($0.13) EPS, Q4 2024 earnings at ($0.13) EPS and FY2025 earnings at ($0.57) EPS.

CVAC has been the subject of a number of other research reports. Guggenheim restated a “neutral” rating on shares of CureVac in a research note on Friday, April 5th. SVB Leerink downgraded CureVac from an “outperform” rating to a “market perform” rating and reduced their price objective for the company from $12.00 to $4.00 in a research note on Thursday. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and one has assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $8.33.

CureVac Stock Performance

Shares of CureVac stock opened at $2.33 on Monday. The stock has a fifty day simple moving average of $3.06 and a 200 day simple moving average of $4.12. CureVac has a 12-month low of $2.21 and a 12-month high of $12.36. The company has a current ratio of 3.56, a quick ratio of 3.41 and a debt-to-equity ratio of 0.06.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of CVAC. SG Americas Securities LLC grew its stake in CureVac by 157.4% in the 3rd quarter. SG Americas Securities LLC now owns 31,497 shares of the company’s stock valued at $215,000 after purchasing an additional 19,259 shares during the period. Chicago Partners Investment Group LLC purchased a new position in shares of CureVac during the 3rd quarter valued at $74,000. TD Asset Management Inc lifted its position in shares of CureVac by 66.8% during the 3rd quarter. TD Asset Management Inc now owns 209,094 shares of the company’s stock valued at $1,428,000 after buying an additional 83,747 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its position in shares of CureVac by 95.6% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,738 shares of the company’s stock valued at $39,000 after buying an additional 2,804 shares during the last quarter. Finally, Platinum Investment Management Ltd. lifted its position in shares of CureVac by 60.6% during the 3rd quarter. Platinum Investment Management Ltd. now owns 363,280 shares of the company’s stock valued at $2,481,000 after buying an additional 137,146 shares during the last quarter. Institutional investors own 17.26% of the company’s stock.

CureVac Company Profile

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratory syncytial virus, rotavirus, malaria, and universal influenza.